Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis
Nipun Verma, Shreya Singh, Gitesh Sawatkar, Virendra Singh – 11 November 2017 – Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious, dermatologic, adverse effect following the use of sofosbuvir. A 35‐year‐old man with genotype 3‐related HCV cirrhosis presented with decompensated ascites and jaundice following 7 weeks of therapy with peginterferon alpha‐2a and oral ribavirin.